World Health Information Science Consultants, LLC
Your Subtitle text
Recent Publications
Schneeweiss S, Seeger JD, Landon J, Walker AM. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008;358:771­83

Schneeweiss S, Walker AM, Seeger JD.  Effect of aprotinin on renal dysfunction. Lancet. 2008 Jul 5;372(9632):26 (letter)

Walker AM, Koro C, Landon J. Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database. Pharmacoepidemiol Drug Saf. 2008 Aug;17(8):760-8

Walker AM, Bennett D. Epidemiology and outcomes in patients with atrial fibrillation in the USA.  Heart Rhythm J 2008 Oct;5(10):1365-1372

Patterson MK, Castellsague J, Walker AM. Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib. Pharmacoepidemiol Drug Saf. 2008 Aug 18;17(10):982-988

Velentgas P, Bohn RL, Brown JS, Chan KA, Gladowski P, Holick CN, Kramer JM, Nakasato C, Spettell CM, Walker AM, Zhang F, Platt R.  A distributed research network model for post-marketing safety studies: the Meningococcal Vaccine Study. Pharmacoepidemiol Drug Saf. 2008 Oct 27;17(12):1226-1234

Loughlin J, Seeger J, Eng PM, Foegh M, Clifford CR, Cutone J, Walker AM. Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives.  Contraception 2008 Nov;78(5):377-383

Brown JS, Moore KM, Braun MM, Ziyadeh N, Chan KA, Lee GM, Kulldorff M, Walker AM, Platt R. Active influenza vaccine safety surveillance: potential within a healthcare claims environment. Med Care. 2009 Dec;47(12):1251-7

Walker AM. Signal detection for vaccine side effects that have not been specified in advance. Pharmacoepidemiol Drug Saf. 2010 Mar;19(3):311-7

Kurth T, Lewis BE, Walker AM. Health care resource utilization in patients with active epilepsy. Epilepsia. 2010 May;51(5):874-82

Walker AM. Orthogonal predictions; Follow-up questions for suggestive data. Pharmacoepidemiol Drug Saf. 2010 May;19(5):529-32

Dreyer NA, Schneeweiss S, McNeil BJ, Berger ML, Walker AM, Ollendorf DA, Gliklich RE; GRACE Initiative. GRACE principles: recognizing high-quality observational studies of comparative effectiveness. Am J Manag Care. 2010 Jun;16(6):467-71

Ziyadeh N, Fife D, Walker AM, Wilkinson GS, Seeger JD. A matched cohort study of the risk of cancer in users of becaplermin. Adv Skin Wound Care. 2011 Jan;24(1):31-9

Walker AM. Identification of esophageal cancer in the General Practice Research Database. Pharmacoepidemiol Drug Saf. 2011 Nov;20(11):1159-67

Gagne JJ, Rassen JA, Walker AM, Glynn RJ, Schneeweiss S. Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules. Epidemiology. 2012 Mar;23(2):238-46.

Gagne JJ, Walker AM, Glynn RJ, Rassen JA, Schneeweiss S. An event-based approach for comparing the performance of methods for prospective medical product monitoring. Pharmacoepidemiol Drug Saf. 2012 Jun;21(6):631-9. http://dx.doi.org/10.1002/pds.2347

Walker AM, Maxim LD, Utell MJ. Are airborne refractory ceramic fibers similar to asbestos in their carcinogenicity? Inhal Toxicol. 2012, Jun;24(7):416-24. Corrigendum. Inhal Toxicol. 2012 Nov;24(13):928-9. http://dx.doi.org/10.3109/08958378.2012.736736

Gagne JJ, Glynn RJ, Rassen JA, Walker AM, Daniel GW, Sridhar G, Schneeweiss S. Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system. Clin Pharmacol Ther. 2012 Jul;92(1):80-6. http://dx.doi.org/10.1038/clpt.2011.369

Brookhart MA, Walker AM, Lu Y, Polakowski L, Li J, Paeglow C, Puenpatom T, Izurieta H, Daniel GW. Characterizing vaccine-associated risks using cubic smoothing splines. Am J Epidemiol. 2012 Nov 15;176(10):949-57. http://dx.doi.org/10.1093/aje/kws158

Seeger JD, Quinn S, Earnest DL, Lembo A, Kuo B, Rivera E, Walker AM. The Zelnorm epidemiologic study (ZEST): a cohort study evaluating incidence of abdominal and pelvic surgery related to tegaserod treatment. BMC Gastroenterology BMC Gastroenterol. 2012 Nov 30;12:171. http://dx.doi.org/10.1186/1471-230X-12-171

Velentgas P, Amato AA, Bohn RL, Chan KA, Cochrane T, Funch DP, Dashevsky I, Duddy AL, Gladowski P, Greenberg SA, Kramer JM, McMahill-Walraven C, Nakasato C, Spettell CM, Syat BL, Wahl PM, Walker AM, Zhang F, Brown JS, Platt R. Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination. Pharmacoepidemiol Drug Saf. 2012 Dec;21(12):1350-8. http://dx.doi.org/10.1002/pds.3321

Walker AM, Patrick AR, Lauer MS, Hornbrook MC, Marin MG, Platt R, Roger VL, Stang P, Schneeweiss S. A tool for assessing the feasibility of comparative effectiveness research. Comparative Effectiveness Research. 2013;3(1):11-20 http://dx.doi.org/10.2147/CER.S40357
Walker AM. Matching on provider is risky. J Clin Epidemiol. 2013;66:S65-S68. http://dx.doi.org/10.1016/j.jclinepi.2013.02.012

Walker AM, Liang C, Clifford CR, Parker C, Feldman A. Cardiac mortality in users of olmesartan, other angiotensin receptor blockers and angiotensin converting enzyme inhibitors. Pharmacoepidemiol Drug Saf. 2014 Apr;23(4):348-56. http://doi: 10.1002/pds.3558

Walker AM. Esophageal cancer and bisphosphonates. J Pharm Drug Devel. 2014;1(3):1-7
Walker AM, Vannappagari V, Buus R, Covington D, Bratton E, Thomson M. Descriptive study of exposure to inhalation zanamivir and pregnancy-related outcomes. J Pharm Drug Devel. 2014;1(5):502-511

Bell C, Charavarty A, Gruber S, Heckbert SR, Levenson M, Martin D, Nelson JC, Sinheiro S, Psaty BM, Reich CG, Schneeweiss S, Shoaibi A, Toh S, Walker AM. Characteristics of study design and elements that may contribute to the success of electronic safety monitoring systems. Pharmacoepidemiol Drug Saf. 2014 Nov;23(11):1223-5. http://dx.doi.org/10.1002/pds.3712

Campbell UB, Walker AM, Gaffney M, Petronis KB, Creanga D, Quinn S, Klein BEK, Laties AM, Lewis M, Sharlip ID, Koitsopoulos F, Klee BJ, Mo J, Reynolds RF. Acute non-arteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors. J Sex Med. 2015 Jan;12(1):139-51 http://dx.doi.org/10.1111/jsm.12726

Lanes S, Brown JS, Haynes K, Pollack MF, Walker AM. Identifying health outcomes in healthcare databases. Pharmacoepidemiol Drug Saf. 2015 Oct;24(10):1009-16. doi:10.1002/pds.3856

Walker AM, Zhou X, Ananthakrishnan AN, Weiss LS, Shen R, Sobel RE, Bate A, Reynolds RF. Computer-assisted expert case definition in electronic health records. Int J Med Inform. 2016 Feb;86:62-70

Gruber S, Chakravarty A, Heckbert SR, Levenson M, Martin D, Nelson JC, Psaty BM, Pinheiro S, Reich CG, Toh S, Walker AM. Design and analysis choices for safety surveillance evaluations need to be tuned to the specifics of the hypothesized drug-outcome association. Pharmacoepidemiol Drug Saf. 2016 Sep;25(9):973-81

Schneeweiss S, Carver PL, Datta K, Galar A, Johnson MD, Johnson MG, Marty FM, Nagel J, Najdzinowicz M, Saul M, Shoham S, Silveira FP, Varughese CA, Wilck M, Weatherby L, Auton T, Walker AM. Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study. J Antimicrob Chemother. 2016 Oct;71(10):2938-44

Walker AM. For drug-induced carcinogenesis, the observations are the hypothesis: Invited editorial for the Mini-Symposium on Cancer Pharmacoepidemiology. Ann Epidemiol. 2016 Nov;26(11):749-750

Walker AM, Weatherby LB, Cepeda MS, Bradford D, Yuan Y.  Possible opioid shopping and its correlates. Clin J Pain. 2017 Nov;33(11):976-982

Walker AM. Tacit knowledge. Eur J Epidemiol. 2017; 32(4):261-267. DOI: 10.1007/s10654-017-0256-9. http://rdcu.be/rZyA

Weiss LS, Zhou X, Walker AM, Ananthakrishnan AN, Shen R, Sobel RE, Bate A, Reynolds RF.  A case study of the incremental utility for disease identification of natural language processing in electronic medical records. Pharm Med 2017 ePub ahead of print. doi: 10.1007/s40290-017-0216-4

Martin D, Gagne JJ, Gruber S, Izem R, Nelson JS, Nguyen MD, Ouellet-Hellstrom R, Schneeweiss SS, Toh S, Walker AM. Sequential surveillance for drug safety in a regulatory environment. Pharmacoepidemiol Drug Saf. 2018; 27(7): 707-712

Wang SV, Gagne JJ, Glynn RJ, Kulldorff M, Pottegård A, Rothman KJ, Schneeweiss S, Walker AM. Reuse of data sources to evaluate drug safety signals: when is it appropriate? Pharmacoepidemiol Drug Saf. 2018;27(6):567-569. doi: 10.1002/pds.4442

Walker AM, Schneeweiss S, DerSarkissian M, Duh MS. Removal of ineligible outcome cases reduces confounding. Clin Epidemiol. 2018;10:575–579. doi: 10.2147/CLEP.S160482.

Walker AM. Conditional power as an aid in making interim decisions in observational studies. Eur J Epidemiol. 2018; May 28. doi: 10.1007/s10654-018-0413-9 [Epub ahead of print]

Walker AM, Coplan PM, Beachler DC. Conditional power for assessing population interventions. J Comp Eff Res 2018 doi: 10.2217/cer-2018-0053 [Epub ahead of print]

Website Builder